Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Emergent BioSolutions Inc. (EBS:NYSE), powered by AI.
Emergent BioSolutions Inc. is currently trading at $8.32. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Emergent BioSolutions Inc. on Alpha Lenz.
Emergent BioSolutions Inc.'s P/E ratio is 8.5.
“Emergent BioSolutions Inc. trades at a P/E of 8.5 (undervalued) with solid ROE of 10.5%.”
Ask for details →Emergent BioSolutions Inc. is a global life sciences company that primarily focuses on the development, manufacturing, and distribution of a wide array of medical products. These products are designed to address public health threats including chemical and biological agents, and infectious diseases. As an important player in the health sector, the company is known for its specialized work in vaccines, antibody therapeutics, and medical devices. Notably, Emergent BioSolutions is a key supplier of biodefense solutions, including anthrax and smallpox vaccines, which are critical to national security programs. The company’s operations span pharmaceutical manufacturing, research, and development, and it works in partnership with both government and commercial entities. Headquartered in Gaithersburg, Maryland, Emergent BioSolutions plays a pivotal role in emergency preparedness, health security, and response solutions, underscoring its importance in global health initiatives and the broader pharmaceutical industry.
“Emergent BioSolutions Inc. trades at a P/E of 8.5 (undervalued) with solid ROE of 10.5%.”
Ask for details →Emergent BioSolutions Inc. (ticker: EBS) is a company listed on NYSE in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 900 employees. Market cap is $445M.
The current price is $8.32 with a P/E ratio of 8.46x and P/B of 0.85x.
ROE is 10.46% and operating margin is 15.92%. Annual revenue is $705M.